Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Senior Strategic Marketing Manager
About the author:
Betsy’s entire marketing career has exclusively focused on the STEM market, with a distinct emphasis on Pharma. During her tenure with Elsevier’s Corporate R&D group, she has managed market segmentation for the pharma and life sciences industry, and launched and manages The Hive, a partnership with a select group of biotech and pharmaceutical start-ups focused on early stage innovation in drug discovery and development. The program promotes collaboration and inspiration across the Pharma & Life Sciences industry. Prior to launching her marketing career, Betsy worked as a management consultant focused on strategy implementation. She holds an MBA from the University of Michigan’s Ross School of Business and a BA from Barnard College of Columbia University.
Posts by Betsy Davis
Posted on July 12th, 2017 in Pharma R&D
In a recent article titled A Spoonful of Kids’ Medicine Makes the Profits Go Up, Kaiser Health News reporter Shefali Luthra wrote about how some pharma industry players may view the need for child-friendly versions of drugs as a “lucrative opportunity”. Luthra specifically cited the opportunities presented by laws like the Best Pharmaceuticals for Children Act Continue reading “Developing Child-Friendly Drugs” »
Posted on July 7th, 2017 in Pharma R&D
Social media is a force to be reckoned with in modern society. Over the last decade, it has changed the way we interact with friends and family, consumes news and entertainment, and do business.
Posted on June 23rd, 2017 in Pharma R&D
It’s been over a year since Elsevier first launched The Hive, and we are inspired by the results that we have seen from this venture. Through frequent blog posts and video interviews, we and everyone who followed the project have been able to see the progress made by the four participating companies: Continue reading “The Hive is open for 2017 applicants” »
Posted on June 19th, 2017 in Pharma R&D
It’s time to re-think our attitude towards rare diseases. Even though relatively few people suffer from any given rare disease, there are so many of these maladies that it’s a surprisingly large swath of the population that is actually victimized by them. Continue reading “So-Called Rare Diseases Are Too Common to Ignore” »